Skip to content
Options Trading Report

Options Trading Report

Primary Menu
  • Home
  • Business
  • Economy
  • Top News
  • Newsletters
  • Home
  • 2026
  • November
  • Regeneron’s New Drug Is Approved. The Better Trade May Be Elsewhere.
  • Top News

Regeneron’s New Drug Is Approved. The Better Trade May Be Elsewhere.

Livsayis wins FDA clearance with a dosing edge, but Alnylam's royalty stream deserves a closer look.
Editor November 20, 2026 4 minutes read
b6fa9a09-fd68-486b-abeb-692bd0522b92

Regeneron scored a genuine first on Wednesday when the FDA approved Livsayis (cemdisiran) for adults with AChR-antibody-positive generalized myasthenia gravis. It is the first and only siRNA therapy cleared in this indication, and the only approved treatment given subcutaneously four times a year. That is a real differentiator in a market where weekly infusions or injections remain the norm. The question for investors is not whether the science is interesting. It is whether Regeneron (REGN) is the right way to own this story, or whether Alnylam Pharmaceuticals (ALNY) is.

The Business

Livsayis works by silencing complement C5, the protein driving the errant immune response behind myasthenia gravis. It was discovered by Alnylam and licensed to Regeneron in 2019 as part of a broad RNAi-focused partnership. In the Phase 3 NIMBLE trial, Livsayis produced a 4.5-point improvement on the MG-ADL daily living score at 24 weeks versus 2.2 points for placebo, a 2.3-point placebo-adjusted gain. That is a meaningful clinical result. Regeneron has not disclosed a U.S. list price in its approval announcement.

Livsayis is Regeneron’s first approved siRNA and first neurology medicine, though the label includes a boxed warning for meningococcal infection and a Risk Evaluation and Mitigation Strategy consistent with other C5 therapies. That safety language matters for launch dynamics. Prescribers and payers have seen it before with rival C5 inhibitors, but it adds friction to onboarding new patients.

Why Wall Street Is Paying Attention

The market’s initial reaction to the approval was underwhelming for REGN. Regeneron shares closed at $923.34 on Thursday, November 19, 2026 as investors weighed the launch opportunity against the broader pipeline. That muted response reflects what the stock already carries: Regeneron reported Q3 2026 revenue of about $5.1 billion and non-GAAP EPS of $20.07. Livsayis enters a Regeneron that is already running hot.

The more interesting number belongs to Alnylam. Per the collaboration agreement, Alnylam receives a $25 million payment on the approval and is eligible for tiered, double-digit royalties of up to 15 percent on global net sales. That is a capital-light royalty, with Regeneron shouldering the commercial execution risk. For ALNY, this is the seventh FDA-approved therapeutic from its RNAi platform, another proof point for a business model that earns on other companies’ wins.

What’s Driving the Opportunity

Livsayis enters a crowded field. The myasthenia gravis market is currently led by argenx and UCB. Argenx’s VYVGART franchise is a formidable incumbent: the company generated $1.7 billion in product net sales in Q3 2026, representing 54 percent year-over-year growth. That is revenue Regeneron will be chipping at from a standing start.

Quarterly dosing is Livsayis’s real pitch, and in a disease where patients are already managing significant burden, four injections per year rather than weekly or biweekly treatments is a clinically meaningful argument. Whether neurologists and payers agree on access and reimbursement at launch remains the central uncertainty.

What Could Go Wrong

Regeneron’s track record on commercial launches is strong, but Livsayis faces headwinds that dosing convenience alone may not solve. Argenx holds label breadth, with VYVGART approved across adult gMG serotypes, and is now pursuing ocular MG as an additional indication. That expanding moat makes gaining share harder, not easier, over time.

For ALNY, the concern is different. Even with the Livsayis approval, sentiment around Alnylam has weakened sharply, with the share price down about 36 percent over the past month and the one-year total return down about 68 percent. A royalty stream worth celebrating does not automatically fix a stock in a sustained downtrend. The royalty dollars are real; whether they are enough to change the technical damage is a separate question.

The Bottom Line

Regeneron is the better business here today. Truist reiterated a Buy with a $982 price target after the approval, and Bank of America reiterated a $1,030 target and Barclays maintained a $1,075 objective, both with buy-equivalent ratings. REGN trades at roughly 20 times trailing earnings with Dupixent still growing and Livsayis adding a new commercial leg in neurology. The valuation is not demanding for the quality on offer.

Alnylam is the cleaner royalty trade on paper, but the chart is broken and the stock demands a higher tolerance for uncertainty. REGN, at current levels, offers a more direct claim on Livsayis upside inside a portfolio that is already outperforming. That combination makes Regeneron the more compelling choice today, with the caveat that this is a launch-stage story and early prescription data will determine whether the dosing advantage translates into durable market share against an argenx franchise that has shown no sign of slowing down.

Post navigation

Previous: Arista Just Posted Its Fastest Revenue Growth Since IPO

Related Stories

e8f94187-6f9a-4aec-b30f-a9a0f556ecf4
  • Top News

Arista Just Posted Its Fastest Revenue Growth Since IPO

Editor November 19, 2026
020d527e-5580-4fab-a701-058d8c109f7f
  • Top News

ALB Is Down 49% and Just Hit a 52-Week Low. The Q3 Numbers Tell a Different Story.

Editor November 17, 2026
0dbe378b-666f-401b-b656-883fa6c36604
  • Top News

Volkswagen Is Cheap at 0.2x Book. That Does Not Make It a Buy.

Editor November 16, 2026

Live Market Pulse

The charting technology is provided by TradingView. Learn how to use theTradingView Stock Screener.

Want More Market News?
Add your email address below to get up to date market news and more!
By submitting your email address, you'll receive a free subscription to Options Trading Report newsletter (Privacy Policy). These newsletters are completely free - and always will be. You will also receive occasional offers about products and services available to you from our affiliates. You can unsubscribe at any time.

Recent Posts

  • Regeneron’s New Drug Is Approved. The Better Trade May Be Elsewhere.
  • Arista Just Posted Its Fastest Revenue Growth Since IPO
  • Walmart Is Priced for a 6% Swing. History Says It Rarely Delivers One.
  • Intel Just Got Its First Real Foundry Customer
  • Disney’s $2 Dividend Looks Generous. Its Cash Flow Has to Back It Up.
  • Nvidia Faces a Two-Front Test as the Chip Rule Goes Live and Xi Meets Trump
  • ALB Is Down 49% and Just Hit a 52-Week Low. The Q3 Numbers Tell a Different Story.

Search

Categories

  • Business
  • Economy
  • Market News
  • Newsletters
  • Top News

You may have missed

b6fa9a09-fd68-486b-abeb-692bd0522b92
  • Top News

Regeneron’s New Drug Is Approved. The Better Trade May Be Elsewhere.

Editor November 20, 2026
e8f94187-6f9a-4aec-b30f-a9a0f556ecf4
  • Top News

Arista Just Posted Its Fastest Revenue Growth Since IPO

Editor November 19, 2026
d16b6bd0-2223-4b54-8a56-4f1fe74a77c8
  • Newsletters

Walmart Is Priced for a 6% Swing. History Says It Rarely Delivers One.

Editor November 19, 2026
21e02d5c-ae4b-416c-83a7-fc8ff5426e2d
  • Business

Intel Just Got Its First Real Foundry Customer

Editor November 19, 2026
  • About Us
  • Disclaimer
  • Privacy Policy
  • Terms of Service/Use Agreement
  • Contact Us
Copyright 2026 © All rights reserved | Options Trading Report | optionstradingreport.com SITE_OK
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}